Tobi Nagel

Dr. Tobi Nagel is Founder and President of Phages for Global Health, a non-profit organization that facilitates the application of phages as antibiotic alternatives in Africa and Asia, where ~90% of the deaths from antimicrobial resistance are expected to occur. Tobi previously spent 15 years in the pharmaceutical industry co-developing drugs that have been tested in >80 clinical trials. She is a Fulbright Global Scholar, with her project being to gather information about how phage-based drugs are currently being regulated in the US, Europe and Australia and sharing that with national leaders in Kenya, Malaysia and Uganda. She was also selected as Moonshot Fellow of the Kravis Lab for Social Impact and an Ad Hoc Reviewer for the US National Institute of Health’s Special Panel on Bacteriophage Therapy. She served as an Advisor to Phages for Human Applications Group Europe, is a founding Editorial Board member of the scientific journal PHAGE and an Advisory Board member for PhagePro, a company developing cholera phages. Tobi did a Postdoctoral Fellowship at the American Hospital in Turkey and completed a PhD in Medical Engineering at the Harvard-MIT Division of Health Sciences and Technology and a BS in Chemical Engineering at Stanford University.